1921
Volume 91, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Growing interest in mass vaccination with oral cholera vaccine in endemic and epidemic settings will require policymakers to evaluate how to allocate these vaccines in the most efficient manner. Because cholera, when treated properly, has a low case fatality rate, it may not be economically feasible to vaccinate an entire population. Using a new publicly available calculator for estimating the cost-effectiveness of mass vaccination, we show how targeting high-risk subpopulations for vaccination could be cost-effective in Bangladesh. The approach described here is general enough to adapt to different settings or to other vaccine-preventable diseases.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0159
2014-12-03
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/91/6/1181.html?itemId=/content/journals/10.4269/ajtmh.14-0159&mimeType=html&fmt=ahah

References

  1. Hamlin C, , 2009. Cholera: The Biography. New York, NY: Oxford University Press.
  2. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J, , 2012. The global burden of cholera. Bull World Health Organ 90: 209218A.[Crossref]
  3. Rouzier V, Severe K, Juste MA, Peck M, Perodin C, Severe P, Deschamps MM, Verdier RI, Prince S, Francois J, Cadet JR, Guillaume FD, Wright PF, Pape JW, , 2013. Cholera vaccination in urban Haiti. Am J Trop Med Hyg 89: 671681.[Crossref]
  4. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, Clemens JD, Cravioto A, Qadri F, , 2013. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 31: 60586064.[Crossref]
  5. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF, , 2013. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis 7: e2465.[Crossref]
  6. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, Jerome JG, Hilaire IJ, Almazor CP, Ternier R, Cadet J, Francois J, Guillaume FD, Farmer PE, , 2013. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 89: 617624.[Crossref]
  7. Ciglenecki I, Sakoba K, Luquero F, Heile M, Itama C, Mengel M, Grais RF, Verhoustraeten F, Legros D, , 2013. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med 10: e1001512.[Crossref]
  8. Saha A, Qadri F, , 2013. Infection: mass vaccination is feasible in response to cholera epidemics. Nat Rev Gastroenterol Hepatol 10: 700701.[Crossref]
  9. Date KA, Vicari A, Hyde TB, Mintz E, Danovaro-Holliday MC, Henry A, Tappero JW, Roels TH, Abrams J, Burkholder BT, Ruiz-Matus C, Andrus J, Dietz V, , 2011. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 17: 21052112.[Crossref]
  10. Prevention and Control of Cholera Outbreaks, 2013. WHO Policy and Recommendations. The World Health Organization Global Taskforce on Cholera Control.
  11. Murray CJL, Evans DB, Acharya A, Baltussen RM, , 2000. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9: 235251.[Crossref]
  12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, , 1996. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276: 12531258.[Crossref]
  13. Russell LG, Gold MR, Siegel JE, Daniels N, Weinstein MC, , 1996. The role of cost-effectiveness analysis in health and medicine. JAMA 276: 11721177.[Crossref]
  14. Fox-Rushby JA, Hanson K, , 2001. Calculating and presenting disability-adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16: 326331.[Crossref]
  15. Musgrove P, Fox-Rushby J, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, . 2006. Cost-effectiveness analysis for priority setting. , eds. Disease Control Priorities in Developing Countries. Second edition. Washington, DC: World Bank, 271285.[Crossref]
  16. Walker DG, Hutubessy R, Beutels P, , 2010. WHO Guide for standardization of economic evaluations of immunization programmes. Vaccine 28: 23562359.[Crossref]
  17. WHO, 2005. Vaccine Introduction Guidelines: Adding a Vaccine to a National Immunization Programme: Decision and Implementation. Geneva: World Health Organization.
  18. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J, , 2011. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 9: 55.[Crossref]
  19. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT, , 2005. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23: 27622774.[Crossref]
  20. Newall AT, Jit M, Hutubessy R, , 2014. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 32: 525531.[Crossref]
  21. Lopez AL, DeRoeck D, Maskery B, Levin A, Bultman J, Kim YE, Mogasale V, , 2012. Country Investment Case Study on Cholera Vaccination: Bangladesh. Seoul, South Korea: International Vaccine Institute.
  22. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL, , 2003. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
  23. Sarker AR, Islam Z, Khan IA, Saha A, Chowdhury F, Khan AI, Qadri F, Khan JA, , 2013. Cost of illness for cholera in a high risk urban area in Bangladesh: an analysis from household perspective. BMC Infect Dis 13: 518.[Crossref]
  24. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, DOMI Cholera Economics Study Group; , 2009. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 12: 899908.[Crossref]
  25. UNICEF, 2012. Guidance Note on the Use of Oral Cholera Vaccines for UNICEF. New York: UNICEF.
  26. Bangladesh Bureau of Statistics, 2013. Population Distribution by Age Group, Sex, and Locality 2008. Dhaka, Bangladesh: Bangladesh Bureau of Statistics.
  27. Sack DA, , 2003. When should cholera vaccine be used in cholera-endemic areas? J Health Popul Nutr 21: 299303.
  28. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD, , 2013. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomized, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 10501056.[Crossref]
  29. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM, , 2011. Oral vaccines for preventing cholera. Cochrane Database Syst Rev 16: CD008603.
  30. Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF, , 2014. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis 8: e2629.[Crossref]
  31. 2014. Oral cholera vaccine campaign among internally displaced persons in South Sudan. Wkly Epidemiol Rec 89: 214220.
  32. Maskery B, DeRoeck D, Levin A, Kim YE, Wierzba TF, Clemens JD, , 2013. Strategy, demand, management, and costs of an international cholera vaccine stockpile. J Infect Dis 208 (Suppl 1): S15S22.[Crossref]
  33. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, Chaignat CL, , 2004. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22: 24442451.[Crossref]
  34. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R, , 2012. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis 6: e1844.[Crossref]
  35. Sack DA, Sack RB, Nair GB, Siddique AK, , 2004. Cholera. Lancet 363: 223233.[Crossref]
  36. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, Calabria B, Chen H, Chugh SS, Cooley R, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, Davis A, Degenhardt L, Díaz-Torné C, Dorsey ER, Driscoll T, Edmond K, Elbaz A, Ezzati M, Feigin V, Ferri CP, Flaxman AD, Flood L, Fransen M, Fuse K, Gabbe BJ, Gillum RF, Haagsma J, Harrison JE, Havmoeller R, Hay RJ, Hel-Baqui A, Hoek HW, Hoffman H, Hogeland E, Hoy D, Jarvis D, Karthikeyan G, Knowlton LM, Lathlean T, Leasher JL, Lim SS, Lipshultz SE, Lopez AD, Lozano R, Lyons R, Malekzadeh R, Marcenes W, March L, Margolis DJ, McGill N, McGrath J, Mensah GA, Meyer AC, Michaud C, Moran A, Mori R, Murdoch ME, Naldi L, Newton CR, Norman R, Omer SB, Osborne R, Pearce N, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Pourmalek F, Prince M, Rehm JT, Remuzzi G, Richardson K, Room R, Saha S, Sampson U, Sanchez-Riera L, Segui-Gomez M, Shahraz S, Shibuya K, Singh D, Sliwa K, Smith E, Soerjomataram I, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Taylor HR, Tleyjeh IM, van der Werf MJ, Watson WL, Weatherall DJ, Weintraub R, Weisskopf MG, Whiteford H, Wilkinson JD, Woolf AD, Zheng ZJ, Murray CJ, Jonas JB, , 2012. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380: 21292143.[Crossref]
  37. Bangladesh, 2014. The World Bank. Available at: http://data.worldbank.org/country/bangladesh. Accessed January 7, 2014.
  38. Levin A, DeRoeck D, Kim YE, Clemens J, Lopez AL, Ali M, Burgess C, Shin S, Wierzba T, , 2012. An Investment Case for the Accelerated Introduction of Oral Cholera Vaccines. Seoul, South Korea: International Vaccine Institute.
  39. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD, , 2005. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366: 4449.[Crossref]
  40. Longini IM, Jr Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD, , 2007. Controlling endemic cholera with oral vaccines. PLoS Med 4: e336.[Crossref]
  41. Clemens J, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, Stanton BF, Kay BA, Walter S, Eeckels R, Svennerholm A-M, Holmgren J, , 1990. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335: 270273.[Crossref]
  42. Azman AS, Luquero FJ, Rodrigues A, Palma PP, Grais RF, Banga CN, Grenfell BT, Lessler J, , 2012. Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau. PLoS Negl Trop Dis 6: e1901.[Crossref]
  43. Chowdhury F, Rahman MA, Begum YA, Khan AI, Faruque AS, Saha NC, Baby NI, Malek MA, Kumar AR, Svennerholm AM, Pietroni M, Cravioto A, Qadri F, , 2011. Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS Negl Trop Dis 5: e999.[Crossref]
  44. Ali M, Goovaerts P, Nazia N, Haq MZ, Yunus M, Emch M, , 2006. Application of Poisson kriging to the mapping of cholera and dysentery incidence in an endemic area of Bangladesh. Int J Health Geogr 5: 45.[Crossref]
  45. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD, , 2008. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2: e173.[Crossref]
  46. Bwire G, Malimbo M, Maskery B, Eun Kim Y, Mogasale V, Levin A, , 2013. The burden of cholera in Uganda. PLoS Negl Trop Dis 7: e2545.[Crossref]
  47. Minetti A, Hurtado N, Grais RF, Ferrari M, , 2013. Reaching hard-to-reach individuals: nonselective versus targeted outbreak response vaccination for measles. Am J Epidemiol 179: 245251.[Crossref]
  48. Mengel MA, Delrieu I, Heyerdahl L, Gessner BD, , 2014. Cholera outbreaks in Africa. Curr Top Microbiol Immunol 379: 117144.
  49. Siddique AK, Zaman K, Baqui AH, Akram K, Mutsuddy P, Eusof A, Haider K, Islam S, Sack RB, , 1992. Cholera epidemics in Bangladesh: 1985–1991. J Diarrhoeal Dis Res 10: 7986.
  50. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW, , 2013. Cholera surveillance during the Haiti epidemic–the first 2 years. N Engl J Med 368: 599609.[Crossref]
  51. Cartwright EJ, Patel MK, Mbopi-Keou FX, Ayers T, Haenke B, Wagenaar BH, Mintz E, Quick R, , 2013. Recurrent epidemic cholera with high mortality in Cameroon: persistent challenges 40 years into the seventh pandemic. Epidemiol Infect 141: 20832093.[Crossref]
  52. Loharikar A, Briere E, Ope M, Langat D, Njeru I, Gathigi L, Makayotto L, Ismail AM, Thuranira M, Abade A, Amwayi S, Omolo J, Oundo J, De Cock KM, Breiman RF, Ayers T, Mintz E, O'Reilly CE, , 2013. A national cholera epidemic with high case fatality rates–Kenya 2009. J Infect Dis 208 (Suppl 1): S69S77.[Crossref]
  53. Mintz ED, Guerrant RL, , 2009. A lion in our village–the unconscionable tragedy of cholera in Africa. N Engl J Med 360: 10601063.[Crossref]
  54. Farmer PE, Ivers LC, , 2012. Cholera in Haiti: the equity agenda and the future of tropical medicine. Am J Trop Med Hyg 86: 78.[Crossref]
  55. Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J, , 2012. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 12: 837844.[Crossref]
  56. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS, , 2012. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine 31: 96108.[Crossref]
  57. Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F, , 2013. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) Diarrhea. Cochrane Database Syst Rev 7: CD009029.
  58. Martin S, Costa A, Perea W, , 2012. Stockpiling oral cholera vaccine. Bull World Health Organ 90: 714.[Crossref]
  59. GAVI, 2013. Cholera Vaccine Investment Strategy. Available at: http://www.gavialliance.org/about/strategy/vaccine-investment-strategy/. Accessed March 11, 2014.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0159
Loading
/content/journals/10.4269/ajtmh.14-0159
Loading

Data & Media loading...

  • Received : 17 Mar 2014
  • Accepted : 09 Sep 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error